A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status
01 Pubblicazione su rivista
Garufi Alessia, Baldari Silvia, Pettinari Riccardo, Gilardini Montani Maria Saveria, D'Orazi Valerio, Pistritto Giuseppa, Crispini Alessandra, Giorno Eugenia, Toietta Gabriele, Marchetti Fabio, Cirone Mara, D'Orazi Gabriella
ISSN: 1756-9966
Tumor progression and tumor response to anticancer therapies may be affected by activation of oncogenic pathways such as the antioxidant one induced by NRF2 (nuclear factor erythroid 2-related factor 2) transcription factor and the pathways modified by deregulation of oncosuppressor p53. Often, oncogenic pathways may crosstalk between them increasing tumor progression and resistance to anticancer therapies. Therefore, understanding that interplay is critical to improve cancer cell response to therapies. In this study we aimed at evaluating NRF2 and p53 in several cancer cell lines carrying different endogenous p53 status, using a novel curcumin compound since curcumin has been shown to target both NRF2 and p53 and have anti-tumor activity.